杭州奥泰生物技术股份有限公司2025年第二次临时股东大会决议公告

Meeting Overview - The second extraordinary general meeting of shareholders was held on November 25, 2025, at the company's conference room in Hangzhou, Zhejiang Province [2] - The total share capital as of the meeting's registration date was 79,280,855 shares, with 973,631 shares in the company's repurchase account not entitled to vote [2] Voting and Attendance - The meeting was convened by the board of directors and chaired by Mr. Gao Fei, utilizing a combination of on-site and online voting methods [4] - All five current directors and three current supervisors attended the meeting, along with the board secretary [4] Resolutions Passed - The following resolutions were approved: - Cancellation of the supervisory board and amendments to the Articles of Association [5] - Revisions to various internal management systems, including: - Shareholders' meeting rules - Board meeting rules - Independent director work system - Related party transaction management system - Prevention of related party fund occupation management system - External guarantee management system - External investment management system - Cumulative voting implementation details - Fundraising management measures [6][7] Legal Compliance - The meeting was witnessed by Shanghai Lifeng Law Firm, confirming that the convening, holding, and voting procedures complied with relevant laws and regulations [8]